Balasubramanian R, Sivasubramanian S, Vijayan V K, Ramachandran R, Jawahar M S, Paramasivan C N, Selvakumar N, Somasundaram P R
Tuberculosis Research Centre (Indian Council of Medical Research), Madras.
Tubercle. 1990 Dec;71(4):253-8. doi: 10.1016/0041-3879(90)90037-9.
A controlled study of three short-course regimens was undertaken in South Indian patients with newly diagnosed, sputum-positive pulmonary tuberculosis. The patients were allocated at random to one of three regimens: a) Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3); b) the same regimen as above but followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5); c) the same as R5 but without rifampicin (Z5). A bacteriological relapse requiring treatment occurred by 5 years in 16.8% of 113 R3, 5.2% of 97 R5, and 20.0% of 115 Z5 patients with organisms sensitive to streptomycin and isoniazid initially. The differences in the relapse rates between the R3 and R5 regimens and the R5 and Z5 regimens were statistically significant (p less than 0.01 for both). Considering patients with organisms initially resistant to streptomycin or isoniazid or both, 7 of 52 patients (4 R3, 2 R5, 1 Z5) had a bacteriological relapse requiring retreatment.
对印度南部新诊断出痰菌阳性肺结核患者进行了三种短程治疗方案的对照研究。患者被随机分配到以下三种治疗方案之一：a）利福平、链霉素、异烟肼和吡嗪酰胺每日服用，持续3个月（R3）；b）与上述方案相同，但随后链霉素、异烟肼和吡嗪酰胺每周两次，再持续2个月（R5）；c）与R5相同，但不含利福平（Z5）。最初对链霉素和异烟肼敏感的113例R3患者中，16.8%在5年内出现需要治疗的细菌学复发；97例R5患者中，5.2%出现复发；115例Z5患者中，20.0%出现复发。R3与R5方案以及R5与Z5方案之间的复发率差异具有统计学意义（两者p均小于0.01）。对于最初对链霉素或异烟肼或两者耐药的患者，52例患者中有7例（4例R3、2例R5、1例Z5）出现需要再次治疗的细菌学复发。
